BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced ...

CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...

Fintel reports that on December 10, 2024, D. Boral Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...

CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...

On Tuesday, CervoMed Inc (CRVO) stock saw a decline, ending the day at $2.16 which represents a decrease of $-8.09 or -78.93% from the prior close of $10.25. The stock opened at $2.53 and touched a ...

CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a ...

Fintel reports that on December 11, 2024, Chardan Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...

CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b ...

Canaccord lowered the firm’s price target on CervoMed (CRVO) to $12 from $65 and keeps a Buy rating on the shares. The firm said they announced ...

CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...

CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.

Recent headlines in health news spotlight several pharmaceutical developments: AbbVie's Parkinson's drug shows promise in ...